Arvinas (NASDAQ:ARVN) Shares Up 7.4% - Time to Buy?

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report)'s stock price rose 7.4% during trading on Tuesday . The stock traded as high as $19.75 and last traded at $19.67. Approximately 144,908 shares changed hands during trading, a decline of 84% from the average daily volume of 886,925 shares. The stock had previously closed at $18.31.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Stephens assumed coverage on shares of Arvinas in a research note on Monday, November 18th. They issued an "overweight" rating and a $55.00 price objective for the company. Guggenheim restated a "buy" rating and set a $57.00 price target on shares of Arvinas in a research note on Wednesday, February 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Arvinas in a research note on Friday, February 7th. Barclays decreased their price objective on Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. Finally, BTIG Research started coverage on Arvinas in a report on Tuesday, December 10th. They issued a "buy" rating and a $69.00 target price on the stock. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat, Arvinas currently has an average rating of "Buy" and a consensus target price of $60.00.

Arvinas Price Performance

The stock has a 50 day moving average of $18.49 and a two-hundred day moving average of $22.94. The stock has a market capitalization of $1.22 billion, a PE ratio of -6.42 and a beta of 1.88.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter last year, the company posted ($2.53) EPS. As a group, research analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Arvinas by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company's stock worth $135,389,000 after acquiring an additional 56,561 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Arvinas by 6.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company's stock worth $78,656,000 after purchasing an additional 249,295 shares during the last quarter. RTW Investments LP boosted its position in Arvinas by 19.8% during the fourth quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock worth $63,919,000 after purchasing an additional 551,979 shares in the last quarter. FMR LLC grew its holdings in Arvinas by 7.6% in the third quarter. FMR LLC now owns 2,883,604 shares of the company's stock valued at $71,023,000 after purchasing an additional 204,317 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Arvinas by 18.7% in the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company's stock valued at $57,371,000 after purchasing an additional 367,343 shares during the last quarter. 95.19% of the stock is currently owned by institutional investors and hedge funds.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.